50% off all subscriptions! ... left. Order NowOrder Now

Weaker Stock
Today EXEL ranks #12793 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$17.06 (-2.40%)

Volume: 1M

Closed: Nov 26, 2021

Hollow Logo Score: -5.276

Exelixis Stock Forecast

$17.06 (-2.40%)

Volume: 1M

Closed: Nov 26, 2021

Score Hollow Logo -5.276

Exelixis Stock Forecast NASDAQ:EXEL

Price Target and Analyst Ratings

Most Recent Rating

On Nov 03, 2021 "HC Wainwright" gave "$65.00 - $52.00" rating for EXEL. The price target was changed from $19.42 to 11.2%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-11-03 $65.00 - $52.00 Target Lowered by HC Wainwright $19.24 $19.42→11.2%
2021-11-03 $32.00 - $31.00 Target Lowered by Royal Bank of Canada $19.24 $19.42→11.2%
2021-11-02 $30.00 - $29.00 Target Lowered by Oppenheimer $21.88 $21.70+0.9%
2021-10-06 Initiated by Jefferies Financial Group $20.90 $20.900.0%
2021-09-20 $37.00 - $36.00 Target Lowered by Truist Securities $19.82 $20.72+0.9%
2021-09-20 $65.00 Reiterated by HC Wainwright $19.82 $19.81→4.4%
2021-09-09 $65.00 Reiterated by HC Wainwright $19.54 $19.81→0.4%
2021-08-06 $35.00 - $64.00 Target Raised by HC Wainwright $17.25 $17.00+1.3%
2021-06-29 Buy Reiterated by HC Wainwright $17.95 $47.00 → $35.00
2021-06-29 Outperform Target Lowered by Oppenheimer $17.95 $35.00 → $27.00
2021-06-28 Buy Target Lowered by Needham & Company LLC $18.02 $33.00 → $30.00
2021-06-15 Buy Initiated by HC Wainwright $22.64 $47.00
2021-04-26 Equal Weight Target Lowered by Morgan Stanley $24.86 $27.00 → $26.00
2021-04-19 Equal Weight Target Lowered by Morgan Stanley $23.74 $27.00 → $26.00
2021-03-30 Outperform Initiated by Credit Suisse Group $21.97 $30.00
2021-03-30 Outperform Initiated by Credit Suisse Group $21.97
2021-03-17 Outperform Initiated by Wolfe Research $23.15 $35.00
2021-03-11 Outperform Initiated by Wolfe Research $22.82
2021-02-16 Overweight Target Raised by Piper Sandler $21.94 $33.00 → $36.00
2021-01-15 Buy Reiterated by William Blair $23.73
2020-12-16 Equal Weight Target Lowered by Morgan Stanley $20.19 $29.00 → $27.00
2020-10-26 Hold Target Raised by Stifel Nicolaus $21.90 $26.00 → $27.00
2020-09-22 Equal Weight Target Raised by Morgan Stanley $25.61 $23.00 → $29.00
2020-09-21 Outperform Target Raised by Oppenheimer $25.81 $33.00 → $37.00
2020-09-21 Overweight Target Raised by Piper Sandler $25.81 $30.00 → $33.00
2020-08-07 Equal Weight Target Raised by Morgan Stanley $22.36 $22.00 → $23.00
2020-07-15 Equal Weight Target Raised by Morgan Stanley $24.37 $21.00 → $22.00
2020-06-02 Buy Reiterated by William Blair $24.27
2020-06-01 Buy Initiated by Oppenheimer $24.14 $28.00 → $32.00
2020-05-14 Positive - Buy Target Raised by SunTrust Banks $24.76 $35.00 → $40.00
2020-05-06 Target Raised by Piper Sandler $26.19 $23.00 → $30.00
2020-05-06 Equal Weight Target Raised by Morgan Stanley $26.19 $20.00 → $21.00
2020-05-06 Market Perform Target Raised by BMO Capital Markets $26.19 $20.00 → $27.00
2020-05-06 Buy Reiterated by Needham & Company LLC $26.19 $33.00
2020-04-21 Outperform Target Raised by Oppenheimer $24.56 $25.00 → $28.00
2020-04-21 Buy Reiterated by Barclays $24.56 $30.00
2020-04-21 Target Raised by Guggenheim $24.56 $27.00 → $32.00
2020-04-20 Buy Target Raised by Needham & Company LLC $23.58 $28.00 → $33.00

EXEL Stock Trend

Given the current short-term trend, the stock is expected to fall -8.12% during the next 3 months and, with a 90% probability hold a price between $15.67 and $19.63 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-11-30 $17.03 $19.19 $21.34
2021-12-01 $17.00 $19.16 $21.31
2021-12-02 $16.97 $19.13 $21.28
2021-12-03 $16.94 $19.10 $21.25
2021-12-06 $16.91 $19.07 $21.22
2021-12-07 $16.88 $19.04 $21.19
2021-12-08 $16.85 $19.01 $21.16
2021-12-09 $16.82 $18.98 $21.13
2021-12-10 $16.79 $18.95 $21.10
2021-12-13 $16.76 $18.92 $21.07
2021-12-14 $16.73 $18.89 $21.04
2021-12-15 $16.70 $18.86 $21.01
2021-12-16 $16.67 $18.83 $20.98
2021-12-17 $16.64 $18.80 $20.95
2021-12-20 $16.61 $18.77 $20.92
2021-12-21 $16.58 $18.74 $20.89
2021-12-22 $16.55 $18.71 $20.86
2021-12-23 $16.52 $18.68 $20.83
2021-12-27 $16.49 $18.65 $20.80
2021-12-28 $16.46 $18.62 $20.77
2021-12-29 $16.43 $18.59 $20.74
2021-12-30 $16.40 $18.56 $20.71
2021-12-31 $16.37 $18.53 $20.68
2022-01-03 $16.34 $18.50 $20.65
2022-01-04 $16.31 $18.47 $20.62
2022-01-05 $16.28 $18.44 $20.59
2022-01-06 $16.25 $18.41 $20.56
2022-01-07 $16.22 $18.38 $20.53
2022-01-10 $16.19 $18.35 $20.50
2022-01-11 $16.16 $18.32 $20.47

About Exelixis

Exelixis Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development pr... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT